eFFECTOR Therapeutics (EFTR)

Executive Summary

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering selective translation regulator inhibitors (STRIs) that target the eIF4F complex to disrupt oncoprotein synthesis and immune evasion in cancer. Its lead candidates, zotatifin (eIF4A inhibitor) and tomivosertib (MNK1/2 inhibitor), have shown mixed clinical results, with several prior trials terminated. However, the company maintains ongoing programs, including a Phase 1/2 trial of zotatifin in combination therapies for solid tumors (NCT04092673, actively recruiting) and a Phase 1 study of tomivosertib in acute myeloid leukemia (NCT05744739). Despite a history of setbacks and a low market capitalization (~$940M), eFFECTOR's novel approach could be validated if current trials demonstrate efficacy. The company's ability to secure additional funding or partnerships will be critical to its survival and potential upside.

Upcoming Catalysts (preview)

• Q3 2026Interim data from Phase 1/2 eFT226 (zotatifin) combination trial in solid tumors30% success
• Q4 2026Update on Phase 1 tomivosertib monotherapy trial in acute myeloid leukemia25% success
• Q3 2026Partnership or financing deal to extend cash runway50% success